Clinical trials: Wet Age Related Macular Degeneration
Neovascular Age Related Macular Degeneration
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A study to use in home technology to reduce the burden of in office visits and injections.
- Trial name
- Liberty (NCT01863199)
- Testing
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Retinal Consultants of Arizona
Wet Age-Related Macular Degeneration
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple…
- Trial name
- NCT04270669
- Testing
- intravitreal injection of RC28-E 0.5mg, intravitreal injection of RC28-E 1.0mg, intravitreal injection of RC28-E2.0mg
- Where
- China
- Volunteers
- 37 people
- Sponsor
- RemeGen Co., Ltd.
Macular Degeneration, Choroidal Neovascularization
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
- Trial name
- NCT00100087
- Testing
- Ocular Brachytherapy
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Theragenics Corporation
Very Low Vision Secondary to Wet Age-related Macular Degeneration
An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)
This study is designed to evaluate the effect of Conbercept therapy on visual acuity and anatomic outcomes and safety observed in subjects with very low vision secondary to wet age-related macular degeneration.
- Trial name
- LAMP (NCT02098720)
- Testing
- Conbercept
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Age-Related Macular Degeneration
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent…
- Trial name
- NCT02357342
- Testing
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Exudative Age-related Macular Degeneration
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
- Trial name
- RAMEN (NCT04640272)
- Testing
- RBM-007
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ribomic USA Inc
Neovascular Age-Related Macular Degeneration
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
- Trial name
- NCT01926977
- Testing
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Neovascular Age-related Macular Degeneration
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
- Trial name
- COAST (NCT04757636)
- Testing
- 2.0 mg OPT-302, 2.0 aflibercept
- Where
- 209 sites in United States, Argentina and 28 more
- Volunteers
- 998 people
- Sponsor
- Opthea Limited
Neovascular(Wet) Age Related Macular Degeneration
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
This is a multicenter, randomized, double-blind, active-controlled, parallel group, Phase III Clinical Trial To Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of CKD-701 and Lucentis® in Patients with…
- Trial name
- NCT04857177
- Testing
- CKD-701, Lucentis®
- Where
- South Korea
- Volunteers
- 312 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Age Related Macular Degeneration
Mobile Clinic - a Cross-sectional Epidemiological Survey
The aim of the study is to find out prevalence of aged-related macular degeneration (AMD) in Slovak Republic. The outcome of the project will be epidemiology survey, prevalence of wet form of AMD in relation to demographic data…
- Trial name
- NCT02055612
- Where
- Slovakia
- Volunteers
- 3,278 people, healthy volunteers welcome
- Sponsor
- Novartis Slovakia, s.r.o.
Wet Age Related Macular Degeneration
Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops
To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
- Trial name
- NCT06969001
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- SCAI Therapeutics
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- ARTEMIS (NCT06856577)
- Testing
- Ixo-vec, Aflibercept
- Where
- 75 sites in United States
- Volunteers
- 311 people
- Sponsor
- Adverum Biotechnologies, Inc.
Macular Degeneration
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD.
- Trial name
- NCT00312351
- Testing
- Pegaptanib sodium
- Where
- United States
- Volunteers
- 262 people
- Sponsor
- Eyetech Pharmaceuticals
Macular Degeneration
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
- Trial name
- NCT00065728
- Testing
- Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD.
- Trial name
- NCT05986864
- Testing
- SKG0106
- Where
- 9 sites in United States, China
- Volunteers
- 68 people
- Sponsor
- Skyline Therapeutics (US) Inc.
Wet Age Related Macular Degeneration, Diabetic Macular Edema
Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study
In this province, optometrists are often responsible for contacting the retinal specialists' office to arrange patients to be examined for suspected emergencies or more routine referrals related to the eye.
- Trial name
- NCT01899963
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- McMaster University
Exudative Age-Related Macular Degeneration
ESBA1008 Microvolume Study
The purpose of this study is to demonstrate a treatment effect of ESBA1008 applied as a microvolume injection or infusion on retinal function and morphology in subjects with exudative age-related macular degeneration (AMD).
- Trial name
- NCT01849692
- Testing
- ESBA1008 solution, Ranibizumab
- Volunteers
- 107 people
- Sponsor
- Alcon Research
Wet Macular Degeneration
Non-Persistence/Non-Adherence (NP/NA) in Wet Age-related Macular Degeneration (wAMD) Patients in Germany
In the research study an observation of patients with wet age-related macular degeneration (wet AMD) will be performed. The term observational study indicates that the current course of therapy and the associated circumstances…
- Trial name
- NCT01448538
- Testing
- Anti-VEGF injections
- Where
- Germany
- Volunteers
- 480 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
This is a clinical study to evaluate the safety, preliminary efficacy, immunogenicity of SKG0106 in subjects with nAMD.
- Trial name
- NCT06213038
- Testing
- SKG0106
- Where
- 3 sites in China
- Volunteers
- 12 people
- Sponsor
- Youxin Chen